You are here

Stem Cell Therapies

STEM CELL TREATMENTS AVAILABLE FOR THE FOLLOWING CONDITIONS

The following conditions have responded well to stem cell treatment.  Most of the following conditions are degenerative.  Treatment success is often measured in terms of improved quality of life by slowing the degenerative effects.

Immunological Diseases Metabolic Diseases
  • Rheumatoid Arthritis
  • Asthma
  • Fibromyalgia
  • Psoriatic Arthritis
  • Sjogren Syndrome
  • Systemic Lupus
  • Renal Insufficiency
  • Cardiac Insufficiency
  • Hepatic Insufficiency
  • Diabetes I and II

 

Ophthalmic Diseases Neurodegenerative Diseases
  • Optic Nerve Atrophy
  • Maculopathy
  • Optic Nerve Atrophy
  • Central Retinal Vascular Occlusion
  • Multiple Sclerosis
  • Parkinson’s Disease
  • Alzheimer’s Disease
  • Amyotrophic Lateral Sclerosis

 

Stem Cell Therapies are unlocking the healing potential of the body

Stem cell therapy regenerates cells and specific organs that could be affected by some disease, disorder or degenerative disease. According to several studies, these stem cells have the ability to differentiate into other types of cells (cardiac cells, bone/cartilage, liver cells, nerve, etc.). In addition, these stem cells have the chemical ability to detect damaged tissues, home in on those tissues and directly repair them. This kind of therapy helps to increase the tissue's functionality, resulting in a considerable improvement of a person’s medical condition and general well-being.


Stem cell treatments have proven effective in conditions where other treatments or therapies have failed.  In addition, many people consider stem cell therapy to be at the forefront of preventive medicine and achievement of optimal health. 

 

WHAT ARE STEM CELLS?

Stem cells are the master cells of the human body. They can divide to produce copies of themselves and many other types of cells. They are found in various parts of the human body at every stage of development from embryo to adult.

There are two distinct types of Stem Cells – one that is for the development of an embryo from a single cell, by giving rise to specialized embryonic tissues, and resulting in the development of a human fetus; and the other which acts as the body’s repair mechanism by differentiating into specialized cells to replace damaged cells with healthy ones. These two types of stem cells are called Embryonic Stem Cells and Adult Stem Cells respectively.


Stem cells are distinguished from other cell types by two important characteristics. First, they are unspecialized cells capable of renewing themselves through cell division, sometimes after long periods of inactivity. Second, under certain physiologic or experimental conditions, they can be induced to tissue or organ-specific cells with special functions. In some organs, such as the gut and bone marrow, become tissue- or organ-specific cells with special functions

 

ADULT STEM CELLS (ASCs)

ASCs are sometimes also referred to as somatic (from Greek Σωματικóς, of the body) stem cells. Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, that lie dormant (quiescent) and non-dividing within different adult human tissues until they are activated by signals from diseased, dying or damaged tissue to not only divide to form more stem cells, but also to differentiate into different types of specialized cells to replenish or regenerate these affected cells. 

ASCs are generally 'multi-potent' lineage-restricted cells with the ability to only differentiate into types of cells Stem Cells predetermined by the germ layer-origin of the tissue within which they reside. They have the ability to divide or self-renew indefinitely, and generate all the cell types of the organ from which they originate, potentially regenerating the entire organ from a few cells. 

Medical interest in adult stem cells has more recently centered on the fact that given the right conditions, some ASCs can differentiate into cell types of germ-origin different to their tissue of origin. This is called Trans-differentiation or Plasticity.

Unlike embryonic stem cells, the use of adult stem cells in research and therapy is not considered to be controversial, as they are derived from adult tissue samples rather than destroyed human embryos.


A stem cell possesses two properties:

 

  • Self-renewal, which is the ability to go through numerous cycles of cell division while still maintaining its undifferentiated state.
  • Multi-potency or multi-differentiative potential, which is the ability to generate progeny of several distinct cell types, (for example glial cells and neurons) as opposed to unipotency, which is the term for cells that are restricted to producing a single-cell type.

 

TYPES OF ADULT STEM CELLS (ASCs) UTILIZED

TMTT affiliate medical professionals primarily utilize adipose tissue, bone marrow and cord blood as a source of stem cells.   The reason for this is because of the larger numbers of stem cells available from these sources;

  • Bone marrow - About 50,000 ASCs can be harvested at any one time.
  • Peripheral blood - About 10,000 ASCs can be harvested at any one time.
  • Adipose tissue (Fat) - About 10 to 50 million stem cells can be harvested at any one time.
  • Cord Blood - a typical cord blood collection in a private bank has a median total nucleated cell count of 470 million MSC.

Stem cells derived from bone marrow are classified as hematopoietic stem cells.   Stem cells derived from adipose tissue and cord blood are classified as mesenchymal stem cells (MSC);


Hematopoietic stem cells
Hematopoietic stem cells are harvested from the bone marrow (typically the femur or iliac crest) and give rise to all the blood cell types.  These cells are also multi-potent and may develop into other cell lines.


Mesenchymal stem cells;
Mesenchymal stem cells (MSCs) are able to differentiate to build bone, cartilage and connective tissue, and they are also provide trophic (growth) support and are very effective at mediating the body’s inflammatory response to damaged or injured cells.


TMTT affiliate medical professionals are currently utilizing mesenchymal stem cells isolated from adipose (fat) tissue and cord blood.

HOW STEM CELLS WORK

Stem cells are capable of performing three important functions :

  • Plasticity: Ability to change into other cell types
  • Homing: To migrate to the site of tissue damage
  • Engraftment:  To unite with other tissues

For example, if stem cells are injected into a patient who has a nerve disorder, those cells should migrate to the site of injury attracted by specific chemicals released by the damaged tissue. The cell, by homing to the damaged area will fuse with the damaged tissue by the process of engraftment and become the same tissue by displaying the property of plasticity. In this example, the stem cell should  become a nerve cell.

The rest of the injected cells, which have not migrated or engrafted, will travel to the bone marrow where they will be stored with the body’s blood cells until needed.  They can still respond, from the bone marrow, to signals from damaged tissue elsewhere in the body and migrate to that site. This is why responses are sometimes not noted until a few months after treatment.

Immediately after the cells are injected, the body secretes numerous chemicals called cytokines. They can cause the remarkable effects sometimes seen immediately after treatment, but are usually transitory.

Stem cell treatment may well hold the key to the rejuvenation of damaged cells/tissues and may give lasting and profound results after stem cell treatment, but it is inappropriate to use the word “cure” at this time because there are specific legal, medical and regulatory protocols that must be attained prior to using the term.  These stem cell procedures are in their infancy, and it will take time to meet these protocols. 

The success of stem cell therapies is not guaranteed.  Results will vary between patients.  Based upon the experience of our affiliated medical professionals, approximately 80% + of patients treated are showing very positive outcomes.

 

STEM CELL TREATMENT AVAILABILITY

The United States and many other Westernized countries have fallen behind in the development and implementation of stem cell therapies.  The reasons for this are beyond the scope of this discussion.  The important point to understand is that effective and safe stem cell procedures are readily available in several  countries today routinely resulting in reversal of a broad range of medical conditions. 

There is a great deal of misunderstanding surrounding stem cell research and therapies.  It is important to understand that the medical procedures outlined herein do not require the use of embryonic stem cells.  TMTT affiliate medical professionals are able to achieve profound results using adult stem cells, most commonly harvested from the patients themselves.

STEM CELL TREATMENTS AVAILABLE FOR THE FOLLOWING CONDITIONS

The following conditions have responded well to stem cell treatment.  Most of the following conditions are degenerative.  Treatment success is often measured in terms of improved quality of life by slowing the degenerative effects. 
 

Immunological Diseases

  • Rheumatoid Arthritis
  • Asthma
  • Fibromyalgia
  • Psoriatic Arthritis
  • Sjogren Syndrome
  • Systemic Lupus

Metabolic Diseases

  • Renal Insufficiency
  • Cardiac Insufficiency
  • Hepatic Insufficiency
  • Diabetes I and II

Ophthalmic Diseases

  • Optic Nerve Atrophy
  • Maculopathy
  • Optic Nerve Atrophy
  • Central Retinal Vascular Occlusion

Neurodegenerative Diseases

  • Multiple Sclerosis
  • Parkinson’s Disease
  • Alzheimer’s Disease
  • Amyotrophic Lateral Sclerosis

 

THE PROCEDURE; HARVESTING AND INFUSION OF AUTOLOGOUS STEM CELLS

Mesenchymal Stem Cells (Adipose tissue)
It is a four hour outpatient procedure involving the following:

Harvest: Using a proprietary but simple procedure similar to tumescent liposuction, 100cc of adipose tissue is harvested from the patient

Breakdown: The adipose tissue is then broken down using a combination of Collagenase Type 1 Solution, and a proprietary Cell Preparation Medium.

Separate: Using standard techniques, the Stromal Vascular Fraction (SVF) which contains Adult Stem Cells (ASCs) is separated from the fat cells.

Isolate: ASCs and other progenitor cells are then isolated from the SVF using standard techniques.

Wash: The cells are then triple-washed with saline to remove any traces of the collagenase and cell preparation medium.

Activate: The isolated ASCs are then suspended in the person's own platelet-rich-plasma (PRP) growth factors and activated with AdiStem's red/yellow/green laser. This 'awakens' or activates the dormant ASCs.

Infuse: The cells are then administered back to the patient through one or more of the following modes of administration:

  1. Intravenous: The ASCs are administered through a standard intravenous drip
  2. Fat Transfer: The ASCs are mixed with the fat filler-biomaterial mix before reintroduction,    and
  3. Topical: The ASCs are administered directly into a localized area different from their tissue of origin

Hematopoietic Stem Cells (Bone Marrow)

The doctor will disinfect the area for bone marrow extraction and anesthetize the area with a small injection.  Once the area has been anaesthetized the bone marrow extraction begins.  During the extraction there is NO pain.

The extraction generally takes between 15 and 20 minutes. Once complete, the doctor will start preparing the bone marrow by activating the stem cells in a closed system (avoiding any contamination).  The serum canalization will be replaced with the bone marrow infusion; this process takes 15 to 20 minutes.

The doctor will take a minimum amount of bone marrow in order to make a target cell count in the laboratory and, if needed, will take another small amount to do one or several injections in other parts of the body depending on the intended tissues to be regenerated. Special injections of stem cells are intended to have direct placement close to related tissues to maximize tissue recovery. Examples of injections are lumbar injection or lymphatic injection, among others.

There is no pain throughout the entire procedure. Only manipulations will be felt in the area of sample taking and in the transfusion area as well. During the following 3 to 5 days, there may be a little bruising in the area of stem cell extraction. The discomfort is generally slight but  pain killers can be prescribed if desired.

 

Cord Blood Collection and Processing

Generally, the source of cord blood stem cells is non-autologous as it comes from an outside source.  

Umbilical cord blood is the blood left over in the placenta and in the umbilical cord after the birth of the baby. The cord blood contains stem cells, including hematopoietic cells. Umbilical cord blood is well-recognized to be useful for treating hematopoietic and genetic disorders.

There are several methods for collecting cord blood. The method most commonly used in clinical practice is the “closed technique”, which is similar to standard blood collection techniques. With this method, the technician cannulates the vein of the severed umbilical cord using a needle that is connected to a blood bag, and cord blood flows through the needle into the bag. On average, the closed technique enables collection of about 75 ml of cord blood.

Collected cord blood is cryopreserved and then stored in a cord blood bank for future transplantation. A cord blood bank may be private (i.e. the blood is stored for and the costs paid by donor families) or public (i.e. stored and made available for use by unrelated donors).

 

STEM CELLS GO TO WORK

Following administration of stem cells;

  • Stem Cells are dispersed into the adjacent tissue and become smooth
  • Stem Cells differentiate into component cell types and integrate with the target tissue or organ
  • Stem Cells begin to secrete several essential growth factors;
    • TGF-αβ (Transforming growth factor alpha & beta)
    • EGF (Epidermal growth factor)
    • FGF (Fibroblast growth factor)
    • IGF (Insulin growth factor)
    • PDEGF (platelet derived epidermal growth factor)
    • PDAF (platelet derived angiogenesis factor)
    • IL-8 (Interleuking-8)
    • TNF-α (Tumor necrosis factor alpha)
    • CTGR (Connective tissue growth factor)GM-CSF (Granulocyte macrophage colony stimulating factor)
    • KGF (Keratinocyte growth factor)
    • High concentration of leukocytes (neutrophils, eosinophils) for microbiocidal events
    • High concentration of wound macrophages and other phagocytic cells, for biological debridement
    • Histamines, Serotonin, ADP, Thromboxane A2, and other vasoactive and chemotactic agents
    • High platelet concentration and native fibrinogen concentration for improved hemostasis
    • Stem Cells start to attract the growth of blood vessels to facilitate tissue formation

 

POST PROCEDURE

After the transfusion, the patient is taken to the recovery area where they will be constantly monitored. Some easily digestible foods and liquids will be provided. Usually, the patient will be able to go home a few hours after the procedure takes place.

A meeting with the doctor will conclude the procedure in order to respond to any questions and to indicate what to expect in the following weeks. Suggestions for optimal health recovery will be shared. The doctor will provide any required medical prescriptions and a 24/7 phone number for patient care assistance.

In the next few days and weeks, the clinic will keep in constant communication with the patient in order to monitor patient  progress and to provide any other required assistance.

 

GOOD MANUFACTURING PRACTICES
  

The medical centers and physicians we use appoint suppliers that ascribe to the highest standards of quality in the Production of all products and stem cells subject to the regulations of Good Manufacturing Practice as prescribed by the World Health Organization.

 

MINIMAL RISK OF REJECTION

Most stem cell treatments performed by participating clinics and hospitals use the patient’s own (autologous) stem cells.  For example, the patient’s own bone marrow cells or fat cells are harvested, processed and re-administered to the patient.  This process virtually eliminates the risk of rejection of the stem cells.


Umbilical cord blood stem cell transplants are less prone to rejection than either bone marrow or peripheral blood stem cells. This is probably because the cells have not yet developed the features that can be recognized and attacked by the recipient's immune system. Also, because umbilical cord blood lacks well-developed immune cells, there is less chance that the transplanted cells will attack the recipient's body.  The risk of graft versus host disease is further minimized by the recent development of elaborate cord blood stem cell purification procedures.